This paper compared analytical methods for epidermal growth factor receptor (EGFR) genotyping using cell-free DNA specimens from patients with non-small cell lung cancer (NSCLC).
Molecular Analysis of Circulating Cell-Free DNA from Lung Cancer Patients in Routine Laboratory Practice: A Cross-Platform Comparison of Three Different Molecular Methods for Mutation Detection.
Bartels S, Persing S, Hasemeier B, Schipper E, Kreipe H, Lehmann U
Purpose
Conclusion
Concordant genotyping results were obtained using the three different methods in 24 of 25 cases (96%). Discrepant results were attributed to a secondary mutation in the primer binding site affecting digital and real-time qRT-PCR results.
Studies (1)
Purpose
This study compared next generation sequencing, digital PCR, and real-time qRT-PCR EGFR genotyping results using cell-free DNA specimens from patients with NSCLC. Blood was obtained from 55 patients with non-small cell lung cancer in cell-free DNA BCT tubes. Tubes were inverted ten times and shipped overnight at room temperature before processing. Plasma was obtained by double centrifugation at 1000 x g for 20 min. A third centrifugation was performed if a visible pellet was still observed. Plasma was stored at -80˚C until cell-free DNA isolation using the QIAamp Circulating Nucleic Acid Kit. DNA was quantified using Qubit 2.0 dsDNA HS assay and DNA integrity was assessed by bioanalyzer. Mutational status was determined in 25 patients by digital PCR, NGS using the IonAmpliSeq Colon and Lung cancer panel v2, and using a TaqMan genotyping assay. NGS alone was performed for an additional 30 specimens. A specimen was considered positive for a mutation by digital PCR when the allele frequency was >0.1% and there were at least five positive wells. A specimen was considered positive for a mutation by NGS when the mutation was present with an allele frequency >0.2% and at least 20 variant reads were found.
Summary of Findings
The majority of isolated DNA was 160-180 bp. The primary EGFR mutation was detected in 10 of 25 cell-free DNA specimens by NGS. Insufficient DNA for analysis was present in three cases for real-time RT-qPCR and one case for digital PCR. One specimen failed NGS twice due to quality issues. For 24 of 25 cases, the genotyping results were concordant among the platforms where analysis was possible. The remaining patient shows a T790M in the NGS assay but was found to be wildtype in the dPCR and real-time PCR assay. The authors attribute this discrepancy to the location of a second mutation in the primer binding site. Using NGS, mutations were found in 30 additional specimens including some cases with multiple mutations.
Biospecimens
FluidPlasmaPreservation Types
FrozenDiagnoses
NeoplasticCarcinomaPlatforms
DNADigital PCRDNASNP assayDNAReal-time qPCRDNANext generation sequencingPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Next generation sequencing Specific Technology platform Digital PCRTaqMan real-time PCRSNP assay Specific Technology platform Digital PCRNGSTaqMan real-time PCR